# US 2003/0228663 A1 · Anti-HER2 antibody variants

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0228663 A1
- Document ID: US20030228663A1
- Status: Published application
- Kind: A1
- Application number: 10/410,894
- Filed: 2003-04-09
- Published: 2003-12-11
- Earliest claimed: 2002-04-10
- Assignees: Genentech, Inc.
- Inventors: Henry B. Lowman; Resi B. Gerstner; Paul J. Carter
- Web page: https://patentgrep.com/patent/US20030228663A1

## CPC

- C07K 16/32: against translation products of oncogenes
- A61J 1/00: Containers specially adapted for medical or pharmaceutical purposes (capsules or the like for oral use A61J3/07; specially adapted for surgical or diagnostic appliances or instruments A61B50/30; containers for radioactive substances G21F5/00)
- A61J 1/18: Arrangements for indicating condition of container contents, e.g. sterile condition
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07K 16/3015: {Breast}
- A61J 2205/30: Printed labels
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61J: CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention concerns novel antibody variants, particularly anti-HER2 antibody variants having substitutions at positions within the variable domains of the heavy and light chains

## Claims

### Claim 1

A polypeptide which comprises an antibody light chain variable domain comprising the hypervariable regions of SEQ ID NO: 1 wherein one or more amino acids selected from the group consisting of Q27(VL); D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), and T94(VL), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the hypervariable regions of SEQ ID NO: 1 comprise amino acid substitutions at one or more positions selected from the group consisting of N30(VL), F53(VL), Y55(VL), H91(VL), Y92(VL), and T94(VL).

### Claim 3 (depends on 1)

The polypeptide of claim 1 wherein the hypervariable regions of SEQ ID NO: 1 comprise one or more amino acid substitutions selected from the group consisting of D28(VL)Q; D28(VL)G; N30(VL)S; T31(VL)S; A32(VL)G; Y49(VL)W, Y49(VL)D, Y49(VL)V; F53(VL)W. F53(VL)V, F53(VL)Q, Y55(VL)W, R66(VL)N, H91(VL)F, H91(VL)Y, Y92(VL)W, and T94(VL)S.

### Claim 4 (depends on 3)

The polypeptide of claim 3 wherein the hypervariable regions of SEQ ID NO: 1 comprise one or more amino acid substitutions selected from the group consisting of D28(VL)Q; D28(VL)G; N30(VL)S; T31(VL)S; A32(VL)G; Y49(VL)W, Y49(VL)D, Y49(VL)V; F53(VL)W, F53(VL)V, F53(VL)Q, Y55(VL)W, R66(VL)N, H91(VL)F, H91(VL)Y, and Y92(VL)W.

### Claim 5 (depends on 4)

The polypeptide of claim 4 wherein the hypervariable regions of SEQ ID NO: 1 comprise one or more amino acid substitutions selected from the group consisting of Y49(VL)D, F53(VL)W, and Y55(VL)W.

### Claim 6 (depends on 5)

The polypeptide of claim 5 comprising two or three or said amino acid substitutions.

### Claim 7 (depends on 6)

The polypeptide of claim 6 comprising all three of said amino acid substitutions.

### Claim 8 (depends on 3)

The polypeptide of claim 3, wherein the hypervariable regions of SEQ ID NO: 1 comprise one or more amino acid substitutions selected from the group consisting of N30(VL)S, F53(VL)W, Y55(VL)W, H91(VL)F, Y92(VL)W and T94(VL)S.

### Claim 9 (depends on 8)

The polypeptide of claim 8, wherein N30(VL) is substituted with S, H91(VL) is substituted with F, and Y92(VL) is substituted with W.

### Claim 10 (depends on 1, 4)

The polypeptide of any one or claims 1, 4, and 5 which is an antibody.

### Claim 11 (depends on 10)

The polypeptide of claim 10, which is a humanized antibody.

### Claim 12 (depends on 10)

The polypeptide of claim 10, which is a human antibody.

### Claim 13 (depends on 10)

The polypeptide of claim 10, which is a antibody fragment selected from the group consisting of Fv, Fab, Fab′ and F(ab′)2 fragments.

### Claim 14

A polypeptide which comprises an antibody heavy chain variable domain comprising the hypervariable regions of SEQ ID NO: 2 wherein one or more amino acids selected from the group consisting of W95(VH), D98(VH), F100(VH), Y100a(VH), and Y102(VH), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.

### Claim 15 (depends on 14)

The polypeptide of claim 14, wherein the hypervariable regions of SEQ ID NO: 2 comprise one or more amino acid substitutions selected from the group consisting of W95(VH)Y, D98(VH)W, D98(VH)R, D98(VH)K, D98(VH)H, F100(VH)P, F100(VH)L, F100(VH)M, Y100a(VH)F, Y102(VH)V, Y102(VH)K, and Y102(VH)L.

### Claim 16 (depends on 15)

The polypeptide of claim 15 wherein the hypervariable regions of SEQ ID NO: 2 comprise one or more amino acid substitutions selected from the group consisting of, D98(VH)W, Y100a(VH)F, and Y102(VH)V.

### Claim 17 (depends on 15)

The polypeptide of claim 15 wherein the hypervariable regions of SEQ ID NO: 2 comprise one or two amino acid substitutions selected from the group consisting of F100(VH)P and Y102(VH)K.

### Claim 18 (depends on 17)

The polypeptide of claim 17 comprising the amino acid substitutions F100(VH)P and Y102(VH)K.

### Claim 19 (depends on 15)

The polypeptide of claim 15 wherein the hypervariable regions of SEQ ID NO: 2 comprise one or two amino acid substitutions selected from the group consisting of F100(VH)P and Y102(VH)L.

### Claim 20 (depends on 19)

The polypeptide of claim 19 comprising the amino acid substitutions of F100(VH)P and Y102(VH)L.

### Claim 21 (depends on 14, 17, 18, 19, 20)

The polypeptide of any one of claims 14 and 17-20, which is an antibody.

### Claim 22 (depends on 21)

The polypeptide of claim 21, which is a humanized antibody.

### Claim 23 (depends on 21)

The polypeptide of claim 21, which is a human antibody.

### Claim 24 (depends on 21)

The polypeptide of claim 21, which is an antibody fragment selected from the group consisting of Fv, Fab, Fab′ and F(ab′)2 fragments.

### Claim 25

An antibody that is capable of binding to the extracellular domain of HER2, which comprises the hypervariable regions of SEQ ID NO: 1 wherein one or more amino acids selected from the group consisting of Q27(VL), D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), and T94(VL), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.

### Claim 26 (depends on 25)

The antibody of claim 25 wherein one or more amino acids selected from the group consisting of N30(VL), F53(VL), Y55(VL), H91(VL), Y92(VL), and T94(VL), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.

### Claim 27 (depends on 25)

The antibody of claim 25 wherein the hypervariable regions of SEQ ID NO: 1 comprise one or more amino acid substitutions selected from the group consisting of D28(VL)Q; D28(VL)G; N30(VL)S; T31(VL)S; A32(VL)G; Y49(VL)W, Y49(VL)D, Y49(VL)V; F53(VL)W, F53(VL)V, F53(VL)Q, Y55(VL)W, R66(VL)N, H91(VL)F, H91(VL)Y, Y92(VL)W, and T94(VL)S.

### Claim 28 (depends on 27)

The antibody of claim 27 wherein the hypervariable regions of SEQ ID NO: 1 comprise one or more amino acid substitutions selected from the group consisting of D28(VL)Q; D28(VL)G; N30(VL)S; T31(VL)S; A32(VL)G; Y49(VL)W, Y49(VL)D, Y49(VL)V; F53(VL)W, F53(VL)V, F53(VL)Q, Y55(VL)W, R66(VL)N, H91(VL)F, H91(VL)Y, and Y92(VL)W.

### Claim 29 (depends on 28)

The antibody of claim 28 wherein the hypervariable regions of SEQ ID NO: 1 comprise one or more amino acid substitutions selected from the group consisting of Y49(VL)D, F53(VL)W, and Y55(VL)W.

### Claim 30 (depends on 29)

The antibody of claim 29 comprising two or three or said amino acid substitutions.

### Claim 31 (depends on 30)

The antibody of claim 30 comprising all three of said amino acid substitutions.

### Claim 32 (depends on 26)

The antibody of claim 26, wherein the hypervariable regions of SEQ ID NO: 1 comprise one or more amino acid substitutions selected from the group consisting of N30(VL)S, F53(VL)W, Y55(VL)W, H91(VL)F, Y92(VL)W, T94(VL)S.

### Claim 33 (depends on 32)

The antibody of claim 32, wherein N30(VL) is substituted with S, H91(VL) is substituted with F, and Y92(VL) is substituted with W.

### Claim 34 (depends on 25, 29)

The antibody of claim 25 or 29, which is a humanized antibody.

### Claim 35 (depends on 25, 29)

The antibody of claim 25 or 29, which is a human antibody.

### Claim 36 (depends on 25, 29)

The antibody of claim 25 or 29, which is a antibody fragment selected from the group consisting of Fv, Fab, Fab′ and F(ab′)2 fragments.

### Claim 37

An antibody that is capable of binding to the extracellular domain of HER2, which comprises an antibody heavy chain variable domain comprising the hypervariable regions of SEQ ID NO: 2 wherein one or more amino acids selected from the group consisting of W95(VH), D98(VH), F100(VH), Y100a(VH), and Y102(VH), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.

### Claim 38 (depends on 37)

The antibody of claim 37 wherein the hypervariable regions of SEQ ID NO: 2 comprise one or more amino acid substitutions selected from the group consisting of W95(VH)Y, D98(VH)W, D98(VH)R, D98(VH)K, D98(VH)H, F100(VH)P, F100(VH)L, F100(VH)M, 100a(VH)F, Y102(VH)V, Y102(VH)K, and Y102(VH)L.

### Claim 39 (depends on 38)

The antibody of claim 38 wherein the hypervariable regions of SEQ ID NO: 2 comprise one or more amino acid substitutions selected from the group consisting of, D98(VH)W, Y100a(VH)F, and Y102(VH)V.

### Claim 40 (depends on 38)

The antibody of claim 38 wherein the hypervariable regions of SEQ ID NO: 2 comprise one or more amino acid substitutions selected from the group consisting of F100(VH)P and Y102(VH)K.

### Claim 41 (depends on 40)

The polypeptide of claim 40 comprising the amino acid substitutions F100(VH)P and Y102(VH)K.

### Claim 42 (depends on 20)

The antibody of claim 20, which is a humanized antibody.

### Claim 43 (depends on 37, 40)

The antibody of claim 37 or 40, which is a human antibody.

### Claim 44 (depends on 37, 40)

The antibody of claim 37 or 40, which is an antibody fragment selected from the group consisting of Fv, Fab, Fab′ and F(ab′)2 fragments.

### Claim 45

An antibody that is capable of binding to the extracellular domain of HER2, which comprises the hypervariable regions of SEQ ID NOs: 1 and 2 wherein one or more amino acids selected from the group consisting of D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), T94(VL), W95(VH), D98(VH), F100(VH); Y100a(VH), and Y102(VH), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.

### Claim 46 (depends on 45)

The antibody of claim 45, wherein the hypervariable regions of SEQ ID NOs: 1 and 2 comprise one or more amino acid substitutions selected from the group consisting of N30(VL)S, F53(VL)W, Y55(VL)W, H91(VL)F, Y92(VL)W, T94(VL)S, D98(VH)W, Y100a(VH)F, and Y102(VH)V.

### Claim 47 (depends on 46)

The antibody of claim 46, wherein N30(VL) is substituted with S, H91(VL) is substituted with F, Y92(VL) is substituted with W, T94(VL) is substituted with S, D98(VH) is substituted with W, Y100a(VH) is substituted with F, and Y102(VH) is substituted with V.

### Claim 48 (depends on 46)

The antibody of claim 46, wherein D98(VH) is substituted with W.

### Claim 49 (depends on 45)

The antibody of claim 45, wherein the hypervariable regions of SEQ ID NOs 1 and 2 comprise one or more amino acid substitutions selected from the group consisting of D28(VL)Q; D28(VL)G; N30(VL)S; T31(VL)S; A32(VL)G; Y49(VL)W, Y49(VL)D, Y49(VL)V; F53(VL)W, F53(VL)V, F53(VL)Q, Y55(VL)W, R66(VL)N, H91(VL)F, H91(VL)Y, Y92(VL)W, T94(VL)S, W95(VH)Y, D98(VH)W, D98(VH)R, D98(VH)K, D98(VH)H, F100(VH)P, F100(VH)L, F100(VH)M, Y100a(VH)F, Y102(VH)V, Y102(VH)K, and Y102(VH)L.

### Claim 50 (depends on 45)

The antibody of claim 45, wherein the hypervariable regions of SEQ ID NOs 1 and 2 comprise one or more amino acid substitutions selected from the group consisting of Y49(VL)D, F53(VL)W, Y55(VL)W, D98(VH)W, F100(VH)P, and Y102(VH)L.

### Claim 51 (depends on 50)

The antibody of claim 50 wherein the hypervariable regions of SEQ ID NOs: 1 and 2 comprise the following substitutions: Y49(VL)D, F53(VL)W, Y55(VL)W, F100(VH)P, and Y102(VH)L.

### Claim 52 (depends on 51)

The antibody of claim 51 wherein the hypervariable regions of SEQ ID NO 2 further comprise the substitution D98(VH)W.

### Claim 53 (depends on 50)

The antibody of claim 50 wherein the hypervariable regions of SEQ ID NOs: 1 and 2 comprise the following substitutions: Y49(VL)D, F53(VL)W, Y55(VL)W, F100(VH)P, and Y102(VH)K.

### Claim 54 (depends on 53)

The antibody of claim 53 wherein the hypervariable regions of SEQ ID NO 2 further comprise the substitution D98(VH)W.

### Claim 55 (depends on 45)

The antibody of claim 45, wherein the binding affinity of the antibody for the HER2 extracellular domain is at least about three-fold better than the binding affinity of humanized monoclonal antibody 4D5-8 for the HER2 extracellular domain.

### Claim 56 (depends on 45, 51, 53)

The antibody of claim 45, 51 or 53, which is a humanized antibody.

### Claim 57 (depends on 45, 51)

The antibody of claim 45, 51, or 53which is a human antibody.

### Claim 58 (depends on 45, 51)

The antibody of claim 45, 51, or 53 which is an antibody fragment selected from the group consisting of Fv, Fab, Fab′ and F(ab′)2 fragments.

### Claim 59

An antibody that is capable of binding to the extracellular domain of HER2 which comprises the light chain variable domain of SEQ ID NO: 1 wherein one or more amino acids selected from the group consisting of Q27(VL), N30(VL), Y49(VL), F53(VL), Y55(VL), H91(VL), Y92(VL), and T94(VL), numbered according to the Kabat numbering system, are substituted with any amino acid other than alanine.

### Claim 60 (depends on 59)

The antibody of claim 59, wherein the light chain variable domain of SEQ ID NO: 1 comprises one or more amino acid substitutions selected from the group consisting of N30(VL)S, Y49(VL)F, Y49(VL)W, F53(VL)W, Y55(VL)W, H91(VL)F, Y92(VL)W, and T94(VL)S.

### Claim 61 (depends on 60)

The antibody of claim 60, wherein N30(VL) is substituted with S, H91(VL) is substituted with F, and Y92(VL) is substituted with W.

### Claim 62

A humanized anti-HER2 antibody 4D5-8, comprising one or more amino acid substitutions selected from the group consisting of N30(VL)S, Y49(VL)F, Y49(VL)W, F53(VL)W, Y55(VL)W, H91(VL)F, Y92(VL)W, T94(VL)S, F100(VL)W, D98(VH)W, Y100a(VH)F, and Y102(VH)V, numbered according to the Kabat numbering system.

### Claim 63

A humanized anti-HER2 antibody 4D5-8 which comprises one or more amino acid substitutions selected from the group consisting of Y49(VL)D, F53(VL)W, Y55(VL)W, F100(VH)P, Y102(VH)K, and Y102(VH)L.

### Claim 64 (depends on 63)

The antibody of claim 63 further comprising the amino acid substitution D98(VH)W.

### Claim 65 (depends on 62)

The antibody of claim 62 comprising the one or more of the amino acid substitutions selected from the group consisting of Y49(VL)D, F53(VL)W, and Y55(VL)W.

### Claim 66 (depends on 62)

The antibody of claim 62 comprising one or more of the amino acid substitutions selected from the group consisting of F100(VH)P, Y102(VH)K, and Y102(VH)L.

### Claim 67 (depends on 64)

The antibody of claim 64 comprising the following amino acid substitutions: Y49(VL)D, F53(VL)W, Y55(VL)W, F100(VH)P, and Y102(VH)K.

### Claim 68 (depends on 64)

The antibody of claim 64 comprising the following amino acid substitutions: Y49(VL)D, F53(VL)W, Y55(VL)W, F100(VH)P, and Y102(VH)L.

### Claim 69 (depends on 60, 61)

An article of manufacture comprising a container, a composition contained therein, and a package insert or label indicating that the composition can be used to treat cancer characterized by the overexpression of HER2, wherein the composition comprises the antibody of claim 60 or 61.

### Claim 70 (depends on 69)

The article of manufacture of claim 69, wherein the cancer is breast cancer.

### Claim 71

An antibody variant of a parent antibody which binds HER2, comprising an amino acid substitution at position 98 of a heavy chain variable domain thereof, and wherein the binding affinity of the antibody variant for HER2 is better than the binding affinity of the parent antibody for HER2.

### Claim 72 (depends on 71)

The antibody variant of claim 71, wherein the amino acid at position 98 is substituted with W.

### Claim 73 (depends on 70)

The antibody variant of claim 70, wherein the parent antibody is a humanized antibody.

### Claim 74

A method for isolating high-affinity variants of a humanized anti-HER2 antibody, comprising:
(a) producing anti-HER2 variants with substitutions at one or more amino acids selected from the group consisting Q27(VL), D28(VL), N30(VL), T31(VL), A32(VL), Y49(VL), F53(VL), Y55(VL), R66(VL), H91(VL), Y92(VL), T94(VL), W95(VH), D98(VH), F100(VH), Y100a(VH), and Y102(VH), within the hypervariable regions of SEQ ID NOs: 1 and 2, wherein numbering is according to the Kabat numbering system;
(b) measuring binding affinities of the variants produced in (a) for HER2 extracellular domain; and
(c) selecting for high-affinity variant.
